You just read:

Pivotal Therapeutics VASCAZEN®-REVEAL Trial Meets Primary and Secondary Endpoints - VASCAZEN® Shows 121% Correction of an Omega-3 Deficiency (p< 0.0001) with a Concomittant 48% Reduction in Triglycerides (p<0.0005)

News provided by

Pivotal Therapeutics Inc.

07 May, 2013, 16:52 BST